61 related articles for article (PubMed ID: 15304162)
1. Outcome of rare primary malignant bone sarcoma treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.).
Palmerini E; Reichardt P; Hall KS; Bertulli R; Bielack SS; Comandone A; Egerer G; Hansmeier A; Kevric M; Carretta E; Hansson L; Jebsen N; Eriksson M; Bruland ØS; Donati DM; Ibrahim T; Smeland S; Ferrari S
Cancer; 2023 Nov; 129(22):3564-3573. PubMed ID: 37530385
[TBL] [Abstract][Full Text] [Related]
2. A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113).
Ray-Coquard I; Hatcher H; Bompas E; Casado A; Westermann A; Isambert N; Casali PG; Pratap S; Stark D; Valverde C; Anand A; Huizing M; Floquet A; Lindner L; Hermes B; Seddon B; Coens C; Jones R; Reed N
Int J Gynecol Cancer; 2020 Oct; 30(10):1633-1637. PubMed ID: 32546554
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy regimen for recurrent uterine leiomyosarcoma.
Hu F; Ye Y; Begum H
J Oncol Pharm Pract; 2024 Mar; 30(2):400-403. PubMed ID: 37787402
[TBL] [Abstract][Full Text] [Related]
4. The value of perioperative imaging in patients with uterine sarcomas.
Nugent EK; Zighelboim I; Case AS; Gao F; Thaker PH; Rader JS; Mutch DG; Massad LS
Gynecol Oncol; 2009 Oct; 115(1):37-40. PubMed ID: 19577795
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study.
Hensley ML; Enserro D; Hatcher H; Ottevanger PB; Krarup-Hansen A; Blay JY; Fisher C; Moxley KM; Lele SB; Lea JS; Tewari KS; Thaker PH; Zivanovic O; O'Malley DM; Robison K; Miller DS
J Clin Oncol; 2018 Oct; 36(33):JCO1800454. PubMed ID: 30289732
[TBL] [Abstract][Full Text] [Related]
6. Malignant mixed mullerian tumors: a SEER database review of rurality and treatment modalities on disease outcome.
Zadeh N; Bhatt A; Sripiparu V; Pasli M; Edwards G; Larkins MC; Peach MS
Front Oncol; 2024; 14():1296496. PubMed ID: 38390260
[TBL] [Abstract][Full Text] [Related]
7. Multimodality treatment of primary cardiac angiosarcoma: A systematic literature review.
Stergioula A; Kokkali S; Pantelis E
Cancer Treat Rev; 2023 Nov; 120():102617. PubMed ID: 37603906
[TBL] [Abstract][Full Text] [Related]
8. Impact of Allocation on Survival During Intermittent Chemotherapy Shortages: A Modeling Analysis.
Hantel A; McManus ML; Wadleigh M; Cotugno M; Abel GA
J Natl Compr Canc Netw; 2022 Apr; 20(4):335-341.e17. PubMed ID: 35390765
[TBL] [Abstract][Full Text] [Related]
9. Uterine Adenosarcoma: a Review.
Nathenson MJ; Ravi V; Fleming N; Wang WL; Conley A
Curr Oncol Rep; 2016 Nov; 18(11):68. PubMed ID: 27718181
[TBL] [Abstract][Full Text] [Related]
10. A review of treatment of uterine leiomyosarcomas.
Reed N
Curr Oncol Rep; 2013 Dec; 15(6):581-7. PubMed ID: 24136566
[TBL] [Abstract][Full Text] [Related]
11. Long Term Prognostic Implications of Expression of Glucose Transporter-1 and Hexokinase II in Patients with Stage I Uterine Leiomyosarcoma.
Tsukada H; Muramatsu T; Miyazawa M; Iida T; Ikeda M; Shida M; Hirasawa T; Kajiwara H; Murakami M; Yasuda M; Mikami M
Acta Histochem Cytochem; 2012 Apr; 45(2):147-54. PubMed ID: 22685357
[TBL] [Abstract][Full Text] [Related]
12. Current management of uterine sarcomas.
García-Martínez E; Egea Prefasi L; García-Donas J; Escolar-Pérez PP; Pastor F; González-Martín A
Clin Transl Oncol; 2011 May; 13(5):307-14. PubMed ID: 21596658
[TBL] [Abstract][Full Text] [Related]
13. Treatment of early uterine sarcomas: disentangling adjuvant modalities.
Zagouri F; Dimopoulos AM; Fotiou S; Kouloulias V; Papadimitriou CA
World J Surg Oncol; 2009 Apr; 7():38. PubMed ID: 19356236
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007.
Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1277-87. PubMed ID: 18506484
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long-term follow-up.
Odunsi K; Moneke V; Tammela J; Ghamande S; Seago P; Driscoll D; Marchetti D; Baker T; Lele S
Int J Gynecol Cancer; 2004; 14(4):659-64. PubMed ID: 15304162
[TBL] [Abstract][Full Text] [Related]
16. Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (adriamycin), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. A prospective trial.
Hempling RE; Piver MS; Baker TR
Am J Clin Oncol; 1995 Aug; 18(4):282-6. PubMed ID: 7625366
[TBL] [Abstract][Full Text] [Related]
17. Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas.
Piver MS; Lele SB; Marchetti DL; Emrich LJ
J Surg Oncol; 1988 Aug; 38(4):233-9. PubMed ID: 3045423
[TBL] [Abstract][Full Text] [Related]
18. [Uterine sarcoma. Retrospective analysis of a series of 22 cases].
Mage P; Chauvergne J; Bui NB; Avril A; Trojani M; Richaud P; Germain T; Maree D
J Gynecol Obstet Biol Reprod (Paris); 1984; 13(7):802-7. PubMed ID: 6549321
[TBL] [Abstract][Full Text] [Related]
19. On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus.
Dusenbery KE; Potish RA; Argenta PA; Judson PL
Am J Clin Oncol; 2005 Jun; 28(3):295-300. PubMed ID: 15923804
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
